Topical sulfasalazine for unresponsive oral lichen planus

• Autores: Sung-Hee Jeong, Jin Chung, Hee Sam Na, Su-Hyeon Park, Yong-Woo Ahn
• Localización: Quintessence International, ISSN-e 0033-6572, Vol. 47, Nº. 4, 2016, págs. 319-327
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: The purpose of this study was to evaluate the usefulness of topical sulfasalazine in the treatment of oral lichen planus (OLP) resistant to corticosteroid therapy.

    Method and Materials: Twenty-one unresponsive OLP patients were treated with topical sulfasalazine 3 times a day for 4 weeks. Each patient's symptoms and lesion size were evaluated at the beginning of therapy, and then after 4 weeks to determine the efficacy of topical sulfasalazine. Inflammatory cytokines levels in saliva were measured by ELISA.

    Results: Seventeen patients (81%) reported improvement of discomfort and 12 patients (57%) had lesions decrease in size over 50%. Patients who had higher levels of IL-1β and IL-8 were more responsive to topical sulfasalazine therapy.

    Conclusion: Topical sulfasalazine should be considered when OLP does not respond to corticosteroid therapy. Furthermore, high concentrations of IL-1β and IL-8 in the saliva are useful indicators for the application of topical sulfasalazine in OLP patients refractory to steroid treatment.